Molecular profiling in advanced non-small-cell lung cancer: preliminary data of the Italian observational prospective study
Élisa Gobbini(Institut Curie), Silvia Novello(University of Turin), Massimo Di Maïo(University of Siena), Vieri Scotti(University of Florence), Salvatore Pisconti(Ospedale SS. Annunziata), Domenico Galetta(Istituto Tumori Bari), Emilio Bria(Università Cattolica del Sacro Cuore), Antônio Rossi(Università Campus Bio-Medico), V. Grecorc(IRCCS Ospedale San Raffaele), Paolo Graziano(Pathological Society), Evaristo Maiello(Casa Sollievo della Sofferenza), Giulio Rossi(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Diego Cortinovis(Azienda Ospedaliera San Gerardo), Angelo Delmonte(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Marcello Tiseo(University of Parma), A. Ceribelli(National Cancer Institute), L Buffoni(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Tindara Franchina(University of Messina), M.R. Migliorino(Nini Hospital), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 0
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k